Zypitamag (Pitavastatin Magnesium) Patent Expiration, LOE Window & CMS Spending
Zypitamag (Pitavastatin Magnesium) by Medicure International: FDA Orange Book core substance LOE 2031-01-19, 8 AB generics, $4.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Medicure International |
| FDA Application & Pathway | N208379 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-01-19 |
| Last Listed Patent or Exclusivity Date | 2031-01-19 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $4.0M |
| 2024 Medicare Part D Spend | $3.9M |
| 2024 Medicaid Spend | $52K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |